Spyre Therapeutics reports third quarter net loss of $11.2 million

Reuters11-05

<a href="https://laohu8.com/S/SYRE">Spyre Therapeutics</a> reports third quarter net loss of $11.2 million

Spyre Therapeutics Inc. reported a net loss of $11.2 million for the third quarter of 2025, an improvement compared to a net loss of $69.0 million in the same period in 2024. Total operating expenses for the quarter were $56.9 million, slightly up from $55.4 million in the prior year. Research and development expenses reached $45.2 million, while general and administrative expenses totaled $11.6 million. The company recorded a gain on sale of in-process research and development asset of $10.0 million for the nine-month period. Interest income for the quarter was $5.4 million, and total other income (expense) was $45.7 million. As of September 30, 2025, Spyre reported $783 million in pro forma cash, cash equivalents, and marketable securities, projecting a cash runway into the second half of 2028. During the period, Spyre announced positive interim Phase 1 results for its SPY003 antibody and initiated a Phase 2 basket study of SPY072 in rheumatic diseases. The company is on track for six proof-of-concept readouts in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581314767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581314767","market":"nz","top_or_hot":-1,"title":"Spyre Therapeutics reports third quarter net loss of $11.2 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> reports third quarter net loss of $11.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported a net loss of $11.2 million for the third quarter of 2025, an improvement compared to a net loss of $69.0 million in the same period in 2024. Total operating expenses for the quarter were $56.9 million, slightly up from $55.4 million in the prior year. Research and development expenses reached $45.2 million, while general and administrative expenses totaled $11.6 million. The company recorded a gain on sale of in-process research and development asset of $10.0 million for the nine-month period. Interest income for the quarter was $5.4 million, and total other income (expense) was $45.7 million. As of September 30, 2025, Spyre reported $783 million in pro forma cash, cash equivalents, and marketable securities, projecting a cash runway into the second half of 2028. During the period, Spyre announced positive interim Phase 1 results for its SPY003 antibody and initiated a Phase 2 basket study of SPY072 in rheumatic diseases. The company is on track for six proof-of-concept readouts in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics reports third quarter net loss of $11.2 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics reports third quarter net loss of $11.2 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a> reports third quarter net loss of $11.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported a net loss of $11.2 million for the third quarter of 2025, an improvement compared to a net loss of $69.0 million in the same period in 2024. Total operating expenses for the quarter were $56.9 million, slightly up from $55.4 million in the prior year. Research and development expenses reached $45.2 million, while general and administrative expenses totaled $11.6 million. The company recorded a gain on sale of in-process research and development asset of $10.0 million for the nine-month period. Interest income for the quarter was $5.4 million, and total other income (expense) was $45.7 million. As of September 30, 2025, Spyre reported $783 million in pro forma cash, cash equivalents, and marketable securities, projecting a cash runway into the second half of 2028. During the period, Spyre announced positive interim Phase 1 results for its SPY003 antibody and initiated a Phase 2 basket study of SPY072 in rheumatic diseases. The company is on track for six proof-of-concept readouts in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL7b8zF2:1","article_id":"2581314767","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581314767","pubTimestamp":1762292287,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spyre Therapeutics Inc. reported a net loss of $11.2 million for the third quarter of 2025, an improvement compared to a net loss of $69.0 million in the same period in 2024. Total operating expenses for the quarter were $56.9 million, slightly up from $55.4 million in the prior year. Research and development expenses reached $45.2 million, while general and administrative expenses totaled $11.6 million. The company recorded a gain on sale of in-process research and development asset of $10.0 million for the nine-month period. Interest income for the quarter was $5.4 million, and total other income  was $45.7 million. As of September 30, 2025, Spyre reported $783 million in pro forma cash, cash equivalents, and marketable securities, projecting a cash runway into the second half of 2028. During the period, Spyre announced positive interim Phase 1 results for its SPY003 antibody and initiated a Phase 2 basket study of SPY072 in rheumatic diseases. The company is on track for six proof-o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SYRE":"SPYRE THERAPEUTICS INC"},"translate_title":"Spyre Therapeutics报告第三季度净亏损1120万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRE":0.9},"content_text":"Spyre Therapeutics reports third quarter net loss of $11.2 million\n    \n\n        Spyre Therapeutics Inc. reported a net loss of $11.2 million for the third quarter of 2025, an improvement compared to a net loss of $69.0 million in the same period in 2024. Total operating expenses for the quarter were $56.9 million, slightly up from $55.4 million in the prior year. Research and development expenses reached $45.2 million, while general and administrative expenses totaled $11.6 million. The company recorded a gain on sale of in-process research and development asset of $10.0 million for the nine-month period. Interest income for the quarter was $5.4 million, and total other income (expense) was $45.7 million. As of September 30, 2025, Spyre reported $783 million in pro forma cash, cash equivalents, and marketable securities, projecting a cash runway into the second half of 2028. During the period, Spyre announced positive interim Phase 1 results for its SPY003 antibody and initiated a Phase 2 basket study of SPY072 in rheumatic diseases. The company is on track for six proof-of-concept readouts in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581314767","isCrawlerRequest":true}